Pulmonary Radiofrequency Ablation - An International Study Survey

Karin Steinke, Patrick E. Sewell, Damien Dupuy, Riccardo Lencioni, Thomas Helmberger, Stephen T. Kee, Augustinus L. Jacob, Derek W. Glenn, Julie King, David L. Morris

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Background: The lung is the most common site for primary cancer worldwide as well as being a common site of metastases for various malignancies. Percutaneous radiofrequency ablation (RFA) is rapidly evolving as a new minimally invasive tool for the treatment of pulmonary tumors. Patients and Methods: A questionnaire was sent by e-mail to 14 centres around the world, which we knew or thought were performing percutaneous pulmonary RFA, to retrospectively survey their experience in this field including the number of ablations done to date, indications, method, peri- and postprocedural complications. Results: Seven centers reported 493 percutaneous procedures in lung tumors. Two deaths have been reported. Complications were subdivided into major and minor complications. Pneumothorax occurred in up to 30% of interventions with less than 10% requiring intercostal drainage. Pleural effusion requiring aspiration occurred in less than 10% of cases. Conclusion: With almost 500 procedures done to date, percutaneous pulmonary RFA appears to be a safe, minimally invasive tool for local pulmonary tumor control with negligible mortality, little morbidity, short hospital stay and gain in quality of life.

Original languageEnglish (US)
Pages (from-to)339-343
Number of pages5
JournalAnticancer Research
Volume24
Issue number1
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Lung
Neoplasms
Postal Service
Pneumothorax
Pleural Effusion
Surveys and Questionnaires
Drainage
Length of Stay
Quality of Life
Neoplasm Metastasis
Morbidity
Mortality
Therapeutics

Keywords

  • Complications
  • Lung
  • Minimally invasive
  • Radiofrequency ablation
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Steinke, K., Sewell, P. E., Dupuy, D., Lencioni, R., Helmberger, T., Kee, S. T., ... Morris, D. L. (2004). Pulmonary Radiofrequency Ablation - An International Study Survey. Anticancer Research, 24(1), 339-343.

Pulmonary Radiofrequency Ablation - An International Study Survey. / Steinke, Karin; Sewell, Patrick E.; Dupuy, Damien; Lencioni, Riccardo; Helmberger, Thomas; Kee, Stephen T.; Jacob, Augustinus L.; Glenn, Derek W.; King, Julie; Morris, David L.

In: Anticancer Research, Vol. 24, No. 1, 01.2004, p. 339-343.

Research output: Contribution to journalArticle

Steinke, K, Sewell, PE, Dupuy, D, Lencioni, R, Helmberger, T, Kee, ST, Jacob, AL, Glenn, DW, King, J & Morris, DL 2004, 'Pulmonary Radiofrequency Ablation - An International Study Survey', Anticancer Research, vol. 24, no. 1, pp. 339-343.
Steinke K, Sewell PE, Dupuy D, Lencioni R, Helmberger T, Kee ST et al. Pulmonary Radiofrequency Ablation - An International Study Survey. Anticancer Research. 2004 Jan;24(1):339-343.
Steinke, Karin ; Sewell, Patrick E. ; Dupuy, Damien ; Lencioni, Riccardo ; Helmberger, Thomas ; Kee, Stephen T. ; Jacob, Augustinus L. ; Glenn, Derek W. ; King, Julie ; Morris, David L. / Pulmonary Radiofrequency Ablation - An International Study Survey. In: Anticancer Research. 2004 ; Vol. 24, No. 1. pp. 339-343.
@article{afa95f6f32c242ef809364c4cd885e13,
title = "Pulmonary Radiofrequency Ablation - An International Study Survey",
abstract = "Background: The lung is the most common site for primary cancer worldwide as well as being a common site of metastases for various malignancies. Percutaneous radiofrequency ablation (RFA) is rapidly evolving as a new minimally invasive tool for the treatment of pulmonary tumors. Patients and Methods: A questionnaire was sent by e-mail to 14 centres around the world, which we knew or thought were performing percutaneous pulmonary RFA, to retrospectively survey their experience in this field including the number of ablations done to date, indications, method, peri- and postprocedural complications. Results: Seven centers reported 493 percutaneous procedures in lung tumors. Two deaths have been reported. Complications were subdivided into major and minor complications. Pneumothorax occurred in up to 30{\%} of interventions with less than 10{\%} requiring intercostal drainage. Pleural effusion requiring aspiration occurred in less than 10{\%} of cases. Conclusion: With almost 500 procedures done to date, percutaneous pulmonary RFA appears to be a safe, minimally invasive tool for local pulmonary tumor control with negligible mortality, little morbidity, short hospital stay and gain in quality of life.",
keywords = "Complications, Lung, Minimally invasive, Radiofrequency ablation, Tumor",
author = "Karin Steinke and Sewell, {Patrick E.} and Damien Dupuy and Riccardo Lencioni and Thomas Helmberger and Kee, {Stephen T.} and Jacob, {Augustinus L.} and Glenn, {Derek W.} and Julie King and Morris, {David L.}",
year = "2004",
month = "1",
language = "English (US)",
volume = "24",
pages = "339--343",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Pulmonary Radiofrequency Ablation - An International Study Survey

AU - Steinke, Karin

AU - Sewell, Patrick E.

AU - Dupuy, Damien

AU - Lencioni, Riccardo

AU - Helmberger, Thomas

AU - Kee, Stephen T.

AU - Jacob, Augustinus L.

AU - Glenn, Derek W.

AU - King, Julie

AU - Morris, David L.

PY - 2004/1

Y1 - 2004/1

N2 - Background: The lung is the most common site for primary cancer worldwide as well as being a common site of metastases for various malignancies. Percutaneous radiofrequency ablation (RFA) is rapidly evolving as a new minimally invasive tool for the treatment of pulmonary tumors. Patients and Methods: A questionnaire was sent by e-mail to 14 centres around the world, which we knew or thought were performing percutaneous pulmonary RFA, to retrospectively survey their experience in this field including the number of ablations done to date, indications, method, peri- and postprocedural complications. Results: Seven centers reported 493 percutaneous procedures in lung tumors. Two deaths have been reported. Complications were subdivided into major and minor complications. Pneumothorax occurred in up to 30% of interventions with less than 10% requiring intercostal drainage. Pleural effusion requiring aspiration occurred in less than 10% of cases. Conclusion: With almost 500 procedures done to date, percutaneous pulmonary RFA appears to be a safe, minimally invasive tool for local pulmonary tumor control with negligible mortality, little morbidity, short hospital stay and gain in quality of life.

AB - Background: The lung is the most common site for primary cancer worldwide as well as being a common site of metastases for various malignancies. Percutaneous radiofrequency ablation (RFA) is rapidly evolving as a new minimally invasive tool for the treatment of pulmonary tumors. Patients and Methods: A questionnaire was sent by e-mail to 14 centres around the world, which we knew or thought were performing percutaneous pulmonary RFA, to retrospectively survey their experience in this field including the number of ablations done to date, indications, method, peri- and postprocedural complications. Results: Seven centers reported 493 percutaneous procedures in lung tumors. Two deaths have been reported. Complications were subdivided into major and minor complications. Pneumothorax occurred in up to 30% of interventions with less than 10% requiring intercostal drainage. Pleural effusion requiring aspiration occurred in less than 10% of cases. Conclusion: With almost 500 procedures done to date, percutaneous pulmonary RFA appears to be a safe, minimally invasive tool for local pulmonary tumor control with negligible mortality, little morbidity, short hospital stay and gain in quality of life.

KW - Complications

KW - Lung

KW - Minimally invasive

KW - Radiofrequency ablation

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=10744220429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220429&partnerID=8YFLogxK

M3 - Article

C2 - 15015618

AN - SCOPUS:10744220429

VL - 24

SP - 339

EP - 343

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -